INTRODUCTION
T h e a nt i p h o s p h o l i p i d s y n d r o m e ( A P S ) i s a n acquired autoimmune disease characterized by the presence of antiphospholipid antibodies (aPL) in patients with a history of venous or arterial thrombosis and/or recurrent miscarriages [1, 2] . Antiphospholipid antibodies belong to a heterogeneous group of autoantibodies with an affinity for anionic phospholipids [3] , including anticardiolipin (aCL), anti-β2 glycoprotein-I (anti-β2GPI), and lupus anticoagulant (LA) antibodies [4] . Prevalence of aPL in the general population ranges between 1% and 5%, but only a minority of aPL-positive subjects develop aPL-related thrombotic complications (APS) [5] . It has been reported that the prevalence of APS is around 40-50 cases per 100,000 persons [6] .
Antiphospholipid antibodies positivity has been associated with a variety of clinical conditions, including infectious, malignant, and autoimmune diseases [7] .
Primary biliary cirrhosis (PBC), autoimmune hepatitis (AIH), and primary sclerosing cholangitis (PSC) are chronic inflammatory liver diseases in which immune reactions against host antigens are thought to be the major pathological J Gastrointestin Liver Dis, March 2015 Vol. 24 No 1: [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] mechanism [8, 9] . Although classically considered as distinct entities, these autoimmune liver diseases (AiLD) may share biochemical and immunological features [9, 10] , such as the positivity of specific autoantibodies [11, 12] , that plays a central role in the diagnosis and classification of AiLD [13] . However, their pathogenic and clinical significance in these liver disorders still remains controversial [14] .
During recent years, a growing number of studies has documented a higher prevalence of aPL in PBC [15] , AIH [16] , and PSC [17] . Moreover, an association between AiLD and aPL-related thrombotic complications has been also reported [18, 19] , suggesting that aPL may not only be an epiphenomenon of AiLD but may also play a pathogenic role. However, these data have been challenged in other studies [20] , and no meta-analytical data providing overall information about this issue are currently available.
The aim of the present study is to perform a systematic review and meta-analysis of case-control and cohort studies evaluating the association of AiLD with the prevalence of aPL and aPL-related thrombotic complications.
METHODS
A protocol for this review was prospectively developed, detailing the specific objectives, the criteria for study selection, the approach to assess study quality, the outcomes, and the statistical methods.
Search strategy
To identify all available studies, a detailed search pertaining to PBC, AIH, PSC, aPL positivity and aPL-related thrombotic complications was conducted according to PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines [21] . A systematic search was performed in major electronic databases (PubMed, Web of Science, Scopus, EMBASE), using the following search terms in all possible combinations: primary biliary cirrhosis, autoimmune hepatitis, primary sclerosing cholangitis, antiphospholipid syndrome, antiphospholipid antibodies, anti-cardiolipin antibodies, anti-beta 2-glycoprotein I antibodies, lupus anticoagulant. The last search was performed on 12 th August 2014. The search strategy was developed without any language restriction.
In addition, the reference lists of all retrieved articles were manually reviewed. Two independent authors (PA and MNDDM) analyzed each article and performed the data extraction independently. In case of disagreement, a third investigator was consulted (LT). Discrepancies were resolved by consensus. Selection results have been reported according to the PRISMA flowchart (Appendix 1).
Data extraction and quality assessment
According to the pre-specified protocol, all studies evaluating the association of PBC, AIH, and PSC with the presence of aPL and aPL-related thrombotic complications were included. Case-reports, case-series without a control group, reviews and animal studies were excluded. The included studies were classified as having a case-control design or a cohort design.
To be included in the meta-analysis, a study had to provide the row number or the percentage of subjects with aCL, anti-β 2 GPI, and/or LA positivity. Studies reporting the prevalence of thrombotic events (both venous and arterial) among AiLD patients with and without aPL positivity were also included.
Antiphospholipid antibodies positivity was defined as the positivity of at least one among IgA, IgM or IgG directed against phospholipids.
In each study, data regarding sample size, major clinical and demographic variables, presence of aCL, anti-β 2 GPI, or LA, and history of thrombosis were extracted.
Given the characteristics of the included studies, the evaluation of the methodological quality of each study was performed with the Newcastle-Ottowa Scale (NOS), which is specifically developed to assess quality of observational studies including case-control and cohort studies [22] . The scoring system encompasses three major domains (selection, comparability and exposure/outcome) and a resulting score range between 0 and 8, a higher score representing a better methodological quality.
Results of the NOS quality assessment are reported in Appendix 2. Differences among cases and controls were expressed as odds ratio (OR) with pertinent 95% confidence intervals (95%CI).
Statistical analysis and risk of bias assessment
The overall effect was tested using Z scores and significance was set at P <0.05 (two-tailed). Statistical heterogeneity among studies was assessed with chi square Cochran's Q test and with I 2 statistic, which measures the inconsistency across study results and describes the proportion of total variation in study estimates, which are due to heterogeneity rather than sampling error. In detail, I 2 values of 0% indicates no heterogeneity, 25% low, 25-50% moderate, and 50% high heterogeneity [23] .
Publication bias was represented graphically by funnel plots of the standard difference in means versus the standard error. Visual inspection of funnel plot asymmetry was performed to address possible small-study effect [24] .
The random-effect method was used.
Sensitivity analyses
We repeated sensitivity analyses by including only studies judged as "high quality" according to NOS (i.e. NOS ≥ to the median value found among included studies).
In order to avoid the risk of data overlap, a further analysis was performed after excluding studies involving the same recruitment Centres and enrolling patients in the same period of time as other included studies.
We also planned to perform separate analyses for casecontrol and cohort studies. 
Sub-group analyses

RESULTS
After excluding duplicate results, the search retrieved 586 articles. Of these studies, 451 were excluded because they were off the topic after scanning the title and/or the abstract, 119 because they were reviews/comments/case reports or they lacked of data of interest. In two studies the on-line full-length version was not available and another 3 studies were excluded after full-length paper evaluation.
Thus, 11 articles were included in the meta-analysis (Appendix 1).
No studies on LA positivity were found and 10 studies (750 patients with AiLD and 1,244 healthy controls) on the prevalence of aCL and anti-β2GPI were included in the final analysis.
Interestingly, some of these studies [15, 17, 25, 26] reported data on more than one AiLD. Overall, 8 studies on PBC (419 cases and 902 controls), 4 on AIH (180 cases and 415 controls), and 3 on PSC (151 cases and 452 controls) were included.
Two out of the 10 included articles and 1 further study [27] also provided data on the prevalence of thrombotic events in AIH patients with and without aPL positivity (3 studies enrolling 67 cases and 75 controls).
In contrast, only one study on PBC [15] and one on PSC [17] reported on the prevalence of aPL-related thrombotic complications, thus no meta-analytical evaluation could be performed for this outcome.
Study characteristics
Major characteristics of the 11 studies included in the meta-analysis are shown in Table I .
The number of patients with PBC varied from 14 to 99, with AIH from 14 to 59, and with PSC from 37 to 73. The mean age varied from 53.7 to 61 years in PBC, from 46.2 to 62 years in AIH, and from 40 to 45 in PSC. The prevalence of male gender varied from 4 to 35.7% among patients with PBC, from 20.3 to 28.6% among those with AIH, and from 54 to 56% among those with PSC. The NOS for quality assessment of included studies showed a median value of 6 for both case-control and cohort studies (Appendix 2).
Anticardiolipin antibodies (aCL) positivity
Seven studies, [15, 17, 25, 26, [28] [29] [30] [32] .
The association with anti-β2GPI positivity was consistently confirmed both by four studies [15, 16, 25, 26] Fig. 2C ).
Thrombotic events
Three studies [15, 16, 27 ] evaluated a total 77 aPL-positive and 65 aPL-negative AIH patients. Only a trend towards a higher prevalence of aPL-related thrombotic complications was found in aPL-positive patients (OR: 1.67, 95%CI: 0.46-6.05; P=0.44, I 2 =0%; P=0.75, Fig. 3) . Because of the lack of studies, no meta-analytical evaluation for this outcome could be performed in PBC and PSC.
Publication bias
The small sample-size and the low number of studies make publication bias assessment unlikely to be performed for all outcomes. 
Sensitivity analysis
The median value of NOS quality assessment was 6 for both case-control and cohort studies. The analyses were repeated by including only studies classified as "high quality" (NOS ≥ 6) [15-17, 25, 26, 28, 31, 32] (Appendix 2) .
Of interest, after excluding studies classified as "low quality" [27, 29, 30] , all results were confirmed (Appendix 3).
All analyses were repeated after excluding studies involving the same recruitment Centres and enrolling patients in the same period of time as other included studies.
Although one study [15] potentially encompassed populations of two other studies [16, 17] , it was the only one among the three that tested only IgA directed against phospholipids. Thus, although evaluating the same subset of patients, the study by Gabeta et al. resulted in different percentages of aPL-positive subjects as compared to the two previous studies. For this reason, it was not excluded from this sensitivity analysis.
On the other hand, we decided to exclude the study by Klein et al. [25] , potentially reporting on the same patients as another study [26] . Of interest, the exclusion of the study by Klein et al. consistently confirmed all results, also determining a significant reduction in the heterogeneity among studies for most outcomes (Table II) . We also performed separate analyses for case-control [15-17, 25-27, 29, 31, 32] and cohort studies [28, 30] . However, considering the relatively low number of cohort studies (n=2), we performed a separate analysis only for case-control studies, which consistently confirmed all results (Table III) .
Sub-group analysis
All studies reported the type of immunoglobulin (IgM, IgG, or IgA) tested. Moreover, 5 out of 10 included studies [16, 17, 25, 26, 30] tested more than one immunoglobulin isotype, providing also separate data for IgM, IgG, and/or IgA.
When separate analyses were performed for each immunoglobulin isotype, most results were confirmed, with the only exception of the association between AIH and IgG directed against phospholipids.
Of interest, a strong association between IgA anti-β2GPI and PBC or AIH emerged from this subgroup analysis (Table  IV) . 
DISCUSSION
Results of the present meta-analysis consistently show an association between AiLD and aPL positivity. In detail, PBC, AIH, and PSC were found to be significantly associated with both aCL and anti-β 2 GPI.
Our findings are strengthened by the results of the sensitivity and subgroup analyses. Indeed, most results were confirmed when separate analyses were performed for each immunoglobulin class (IgM, IgG, or IgA) directed against phospholipids.
The clinical relevance of our findings lies in the association of aPL positivity with serious clinical complications, such as venous and arterial thrombosis or recurrent spontaneous abortions [33] . The association between AiLD and aPL-related thrombotic complications has been documented by several J Gastrointestin Liver Dis, March 2015 Vol. 24 No 1: [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] studies [18, 27, 34, 35] . However, most of these studies are case-reports. Thus, the clinical significance of aPL in patients with PBC, AIH, and PSC still remains controversial.
For this reason, we also tried to assess whether aPL positivity was associated with an increased risk of aPL-related thrombotic events in patients with AiLD. However, none of included studies was specifically designed to evaluate this outcome. Given the little amount of data on history of previous thrombotic events, we failed to demonstrate an association between aPL positivity and the risk of thrombosis in these clinical settings. Only a trend towards a higher prevalence of thrombotic complications in AIH patients with aPL was found.
Overall, our data consistently show an increased prevalence of aPL in PBC, AIH, and PSC. The high frequency of aPL in AiLD but also in viral hepatitis [36, 37] and other liver diseases [38] raises the possibility of common underlying mechanisms. One attractive hypothesis could be the induction by chronic stimulus of neoantigens derived from disruption of hepatocyte membranes [16] . Cross-reactivity might be another mechanism with a crucial pathogenic role [30] . For example, it is known that mitochondria contain cardiolipin [39] and the association between PBC and aCL might be explained by cross-reactivity between aCL and anti-mitochondrial antibodies [30] .
Although specific factors resulting in the aPL induction are largely unknown, the critical issue that still remains unsolved is whether these autoantibodies are pathogenic or not in these clinical settings. A recent meta-analysis concluded that aCL positivity is predictive of both venous and arterial thrombosis, while anti-β 2 GPI are associated with an increased risk of venous events [40] . Growing interest has been raised by IgA anti-β 2 GPI as a novel subgroup of clinically relevant aPL [41] . IgA anti-β2GPI have shown a significant association with thrombotic events [42] . Such a clinical relevance has been recently recognized by the inclusion of these autoantibodies among the aPL tests in the novel Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for systemic lupus erythematosus [43] . Of interest, when separately analyzing positivity of different immunoglobulin isotypes directed against phospholipids, we found a strong association of IgA anti-β 2 GPI with both PBC (OR: 68.18; P<0.001) and AIH (OR: 47.35; P=0.02).
The clinical relevance of aPL positivity is of further interest in PBC because these autoantibodies may be implicated in the vasculopathy of the small vessels surrounding the bile ducts [32] . This vasculopathy has been postulated to play a role in the pathogenesis of PBC [44] and of PBC-associated portal hypertension [45, 46] . Thus, aPL may not only be an epiphenomenon of PBC but they may also contribute to its pathogenesis [32] .
However, we have to consider the possibility that aPL are only a marker of these liver disorders rather than a trigger of vascular events mediated by an immunological process. The potential implication of aPL in these clinical settings requires to be assessed in large prospective studies.
Some potential limitations of our study need to be discussed. First, studies included in our meta-analysis have different inclusion and exclusion criteria and we cannot exclude that the concomitant presence of other demographic and clinical variables may influence our results on aPL positivity and thrombotic risk. Since meta-analysis is performed on aggregate data, the meta-regression analysis would have allowed for the adjustment for these potential confounders. However, based on Cochrane's collaboration guidelines, a meta-regression approach is effective when a co-variate is reported by at least 10 studies [47] and several missing information is present in each included study. Thus, no meta-regression analysis could be performed and caution is necessary in overall results interpretation.
As a further potential source of bias, we have to consider that testing for different types of aPL was characterized by lack of standardization of the assays in the past years. This may limit the comparability of studies and, in turn, the relevance of our results. However, by sorting studies according to publication date, no differences were found (data not shown). This may partially offset the above limitation.
CONCLUSION
In our meta-analysis, PBC, AIH, and PSC appeared significantly associated with aPL positivity while the association with aPL-related thrombotic complications should be further studied. We do not believe that patients with AiLD should be systematically tested for these autoantibodies. On the other hand, the concomitant presence of other thrombotic risk factors may suggest a meticulous screening for aPL positivity, with the aim to plan more specific prevention strategies. Additional and specifically designed prospective studies are required in order to establish the clinical significance of aPL in AiLD and the optimal management of these patients. 
